Crescent Biopharma, Inc.
CBIOHealthcareNASDAQBiotechnology · Last scanned Jul 18, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Crescent Biopharma, Inc. focuses on Biotechnology services and products. Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. At a $526.1M market cap, Crescent Biopharma, Inc. ranks as a small-cap company within healthcare. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003.
Market Cap
$526.1M
Beta
—
P/E (TTM)
—
P/E (Fwd)
-4.96
EPS (TTM)
$-5.74
EPS (Fwd)
$-2.98
ROE
—
ROA
—
Cash
$189.2M
Total Debt
$1.5M
Free CF
—
52W Change
10.6%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $189.2M in cash comfortably exceeding the $1.5M debt load. A net cash position generally provides financial flexibility during uncertain economic periods.
With cash comfortably exceeding debt, CBIO has financial flexibility that may help navigate uncertain periods. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Crescent Biopharma, Inc.'s trajectory.